Symbols

BioHarvest Sciences Q2 2025: Unpacking Contradictions in CDMO Revenue Contributions and Product Launches

Generated by AI AgentAinvest Earnings Call Digest

Monday, Aug 11, 2025 1:33 pm ET1min read

BHST--

Aime Summary

- BioHarvest Sciences reported $8.5M Q2 2025 revenue, up 41% YoY driven by vinia.com, Amazon sales, and CDMO services.

- Gross margin expanded 800 bps to 60% via scale, technology leverage, and improved manufacturing yields.

- VINIA's U.S. active customers surpassed 65,000, with Amazon listing as #1 resveratrol product boosting subscription growth.

- CDMO division advanced first project to Stage 2 using proprietary botanical synthesis technology for high-consistency compound production.

- Earnings call highlighted contradictions around CDMO revenue contribution timing, electrolyte product launch delays, and Tate & Lyle partnership progress.

CDMO contribution to revenue, CDMO pipeline progress, electrolyte hydration product launch timeline, Tate & Lyle partnership progress are the key contradictions discussed in BioHarvest Sciences' latest 2025Q2 earnings call.

Revenue Growth and Earnings Performance:
- BioHarvest SciencesBHST-- reported revenue of $8.5 million for Q2 2025, up 41% year-over-year.
- The increase was driven by balanced performance across vinia.com and AmazonAMZN--, along with contributions from the CDMO services division.

Gross Margin Expansion:
- Gross margin expanded by 800 basis points to 60%, up from 52% in the same year ago quarter.
- This improvement was due to scale and technology leverage, as well as enhanced manufacturing yields.

Direct-to-Consumer Growth:
- The number of active VINIA customers in the U.S. reached approximately 65,000, with subscription customers representing the majority.
- This growth was supported by strong performance on Amazon, with VINIA being the #1 resveratrol-only product sold on Amazon.com.

CDMO Division Milestones:
- A CDMO research contract successfully completed Stage 1, becoming the first project to advance to Stage 2.
- Advancements in the CDMO division are attributed to the company's unique botanical synthesis technology, which enables the production of life-changing compounds with high consistency and economic viability.

Ainvest Earnings Call Digest

Discover what executives don't want to reveal in conference calls

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue